Josep Mallolas

Josep Mallolas

Auto-generated profile, based on publicly available information

Josep Mallolas

HIV Unit, Infectious Diseases Service, Hospital Clinic, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
AWAlexander Wong
Alexander Wong
DGDeborah Goldstein
Deborah Goldstein
JMJosep Mallolas
Josep Mallolas
EDEdwin DeJesus
Edwin DeJesus
MJMargaret Johnson
Margaret Johnson
HTHedy Teppler
Hedy Teppler

1 January 2000 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JBJuan Berenguer
Juan Berenguer
JMJosep Mallolas
Josep Mallolas
We report the compassionate use of intravenous cidofovir for the treatment of cytomegalovirus retinitis in 51 patients with AIDS who were receiving h

1 February 2007 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
MLMontserrat Laguno
Montserrat Laguno
MLMaría Larrousse
María Larrousse
JMJavier Murillas
Javier Murillas
JBJose L. Blanco
Jose L. Blanco
ALAgathe León
Agathe León
JMJosep Mallolas
Josep Mallolas
As a result of adverse events, a moderate rate of virologic response, and high costs associated with hepatitis C virus (HCV) therapy, finding early markers of sustained treatment response is a clinical priority. In the HCV-monoinfected population, a reduction >or=2 log in plasma HCV RNA at week 12 of therapy (early virologic response [EVR]) predicts a sustained virologic response (SVR). Few data are available in HIV/HCV-coinfected patients, however. A subanalysis of data from HIV/HCV-coinfected patients treated with pegylated interferon-alpha-2b (PEG, 100-150 mug/wk) or interferon-alpha-2b (IFN, 3 MIU 3 times per week) plus ribavirin (RBV, 800-1200 mg/d) was conducted in a randomized single-center clinical trial. The duration of treatment was 48 weeks (only 24 weeks for HCV genotype 2 or 3 with a baseline HCV RNA level <800,000 IU/mL). Ninety-five patients were randomized (43 assigned to IFN + RBV and 52 assigned to PEG + RBV). Eighty patients completed at least 12 weeks on therapy and were included in the EVR analysis. Thirty-five (43%) of them attained an SVR (56% and 30% of patients treated with PEG and IFN, respectively; P = 0.026). An EVR occurred in 55 (69%; 80% of PEG + RBV group and 56% of IFN + RBV group). Overall, 35 of 55 patients with an EVR were sustained responders, yielding a positive predictive value of 64% (70% in PEG + RBV arm and 55% in IFN + RBV arm). None of the patients who demonstrated an HCV RNA decline of <2 logs at week 12 reached an SVR (negative predictive value of 100%). Our results confirm the utility of an EVR to predict the chance of the lack of an SVR in HIV/HCV-coinfected patients, particularly those treated with PEG.

14 January 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
AFAlberto Foncillas
Alberto Foncillas
JAJuan Ambrosioni
Juan Ambrosioni
ASAbiu Sempere
Abiu Sempere
LBLeire Berrocal
Leire Berrocal
JJJúlia Calvo Jimenez
Júlia Calvo Jimenez
MLMontserrat Laguno
Montserrat Laguno
Background: Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) therapy for HIV, lacks activity against hepatitis B virus (HBV). We evaluate HBV serological profiles and risk of HBV reactivation (HBVr) or incident infection (HBVi) in people with HIV (PWH) switching to LA-CAB/RPV. Methods: Prospective cohort study of PWH initiating LA-CAB/RPV at Hospital Clínic Barcelona between February/2023 and February/2025. HBV serology, vaccination status, and liver function tests (LFTs) were assessed at baseline. Follow-up LFTs were performed routinely (weeks 12, 28, and every 6 months), and HBV serology/DNA assessed if abnormal LFTs, acute hepatitis or clinical suspicion of reactivation. HBVr was defined as conversion from HBsAg negative to positive or detectable HBV DNA in anti-HBc-positive/HBsAg-negative individuals, or as HBV DNA ≥1 log increase or ≥100 IU/mL in chronic HBV (HBsAg-positive) participants. HBVi was defined as HBsAg seroconversion in HBV unexposed individuals. Results: Among 741 participants-92% cis-gender male, median age 43 (IQR 35–52)-454 (61%) had vaccine-induced immunity and 25% had prior HBV exposure (anti-HBc-positive), with 3% showing isolated anti-HBc. Median follow-up was 54 weeks (IQR 28–77). No HBVr or HBVi were observed in people without chronic hepatitis at baseline. Four individuals (0.5%) with unnoticed chronic HBV infection (HBsAg-positive) started LA-CAB/RPV; two developed clinical HBVr and two remained stable after regimen switch, all four switched back to tenofovir-containing therapy. Transaminase elevations during follow-up occurred in 17% of the cohort, regardless of HBV serostatus. Conclusions: LA-CAB/RPV appears safe in individuals with prior HBV exposure, including isolated anti-HBc. Comprehensive HBV screening, vaccination, and liver monitoring are essential.

14 October 2005 in AIDS
Verified
Journal Article
Open access
ALAgathe León
Agathe León
JMJosep Mallolas
Josep Mallolas
EMEsteban Martinez
Esteban Martinez
ELElisa De Lazzari
Elisa De Lazzari
TPTomàs Pumarola
Tomàs Pumarola
JGJosep María Gatell
Josep María Gatell
We evaluated the virological outcome of tenofovir plus didanosine-based regimens in 67 HIV-suppressed patients. After a median follow-up of 26 months (IQR 10.5–40.5), 12 (18%) discontinued the therapy because of virological failure. At virological failure ‘de novo’ selected mutations were identified in 11 of the 12 failing patients, including the K65R mutation in seven patients. These results argue against the use of tenofovir–didanosine not only in naive patients, but also in previously suppressed patients.

12 February 2025 in HIV Research & Clinical Practice
Verified
Journal Article
Open access
BTBenoit Trottier
Benoit Trottier
CYChia-Jui Yang
Chia-Jui Yang
DWDai Watanabe
Dai Watanabe
GMGiulia Marchetti
Giulia Marchetti
DEDaniel Elbirt
Daniel Elbirt
JMJosep Mallolas
Josep Mallolas
BICtegravir Single Tablet Regimen (BICSTaR) is an observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people with HIV. To present final pooled 24-month outcomes for the full cohort. Prospective data were pooled from TN and TE adults with HIV initiating B/F/TAF in routine clinical practice across 14 countries (data collection: 25/06/2018-29/12/2023). Outcomes at 24 months included virologic suppression (HIV-1 RNA <50 copies/mL), immunologic effectiveness (change in CD4 cell count and CD4/CD8 ratio), persistence, and safety. Outcomes were also analysed in key populations. Of 2,074 (483 TN, 1,591 TE) participants included, most were male (85%), White (70%), and had ≥1 comorbidity (66%). Median (Q1, Q3) age was 45 (35, 54) years. At 24 months, 94% of TN and 96% of TE participants had HIV-1 RNA <50 copies/mL (missing = excluded analysis). These values were 88% and 86%, respectively, in a discontinuation = failure analysis. Effectiveness remained high across all key populations at 24 months. Median (Q1, Q3) CD4 count increased by 257 (127, 447) cells/µL in TN and 40 (-70, 153) cells/µL in TE participants (both p < 0.001). There was no reported treatment-emergent resistance to B/F/TAF. Persistence was high at 24 months (TN, 95%; TE, 91%). Drug-related adverse events occurred in 11% of TN and 12% of TE participants, leading to B/F/TAF discontinuation in 5%. B/F/TAF was generally well tolerated over 24 months, with high effectiveness and persistence observed among a broad range of people with HIV.